Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Be nice to c the new sites & patient enrollments

<< Previous

Bullboard Posts

Next >>

Comment by floatinketuckyon Mar 26, 2021 10:15pm

148 Views

Post# 32891901

RE:RE:RE:Be nice to c the new sites & patient enrollments

10 patients early 2021 for 25 for Breakthrough Designation

Shawn Shirazi, PhD, Chief Executive Officer, Theralase®, stated, "Each CSS Theralase launches for Study II will aid in our objective of enrolling and treating 10 patients in early 2021 to achieve a total of 25 patients for potential Breakthrough Designation Approval and approximately 75 to 100 additional patients in 2021 / 2022."

greaterfoolFred wrote:

biggerr wrote: I agree, it's been a very slow pace so far - we'll be celebrating 3 years next month since the 2 patients got cured of their bladder cancer in the Phase I and since then no real progress. Hopefully things will speed up now with the 6th US site added, all they need is 9 more patients treated - how hard could that be, they could do it in one week for gawd sake

I think we need to get real with the numbers. FDA isn't going to let them leave the five with failed treatments out of the calculations like was done in the last quarterly report. They will have to include all of the first 12 or none of them. I think that our real 25 starts with patient 13, after the protocol was corrected. So we really need 37. C'est la vie.
Good luck all.
And as an aside, on a topic in another thread, sometimes a B12 supplement can cut down the nightly number of bathroom trips.